Innocan Pharma Corporation announced the entering into of a wide-scope commercial distribution agreement with UAB Medexy. As part of the multi-year Distribution Agreement, UAB Medexy has an exclusive right to distribute both of Innocan's SHIR and RELIEF&GO brands in Lithuania, Latvia & Estonia, based on an agreed purchase forecast. UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF &GO products.

UAB Medexy has a reputation as a key Eastern European player in the import and distribution of cosmetic products and medical devices. It has been very active in the Lithuanian dermo-cosmetics market for the past 17 years, positioning it as one of the major players in its industry. The CBD skin care market is estimated to reach USD 10,376.4 M by 2028, according to CBD skin care Market | Global Sales Analysis Report 2028.

Innocan Pharma and SHIR/RELIEF&GO will now be stepping-up to become market leaders in many European countries.